Moleculin Biotech
Most recent annual filing: 2026-03-18
- Annamycin filing3Q 2026Annamycin filing, 3Q 2026, notable
- WP1066 readout2H 2026WP1066 readout, 2H 2026, notable
- Annamycin pancreatic Ph1 start2H 2026Annamycin pancreatic Ph1 start, 2H 2026, routine
- Annamycin enrollment doneSep 2026Annamycin enrollment done, Sep 2026, routine
- Annamycin toplineDec 2026 – Feb 2027Annamycin topline, Dec 2026 – Feb 2027, thesis-defining
- Annamycin Ph3 start1H 2027Annamycin Ph3 start, 1H 2027, routine
- Annamycin financingJan 30, 2027Annamycin financing, Jan 30, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (10 active programs)
Annamycin
L-Annamycin · naxtarubicin Small Molecule Target: topoisomerase II
WP1066
Small Molecule Target: p-STAT3, STAT3, c-Myc, HIF-1α
- Glioblastoma
- Pediatric Brain Tumors
- Glioblastoma
Annamycin
naxtarubicinAnnamycin
naxtarubicin · L-Annamycin · MB-108 · MB-109Annamycin
naxtarubicin · L-Annamycin · MB-110WP1122
Small Molecule Target: glycolysis
- Undisclosed indication
Annamycin
naxtarubicin · L-AnnamycinDiscontinued (5)
- Annamycin — Soft Tissue Sarcoma · Phase 1 completed; Phase 2 completed; CSR finalized
- WP1220 — Cutaneous T-Cell Lymphoma · Concluded in February 2023
- WP1122 — COVID-19 · Concluded and CSR completed
- Annamycin — Soft Tissue Sarcoma Lung Metastases · Trial completed; CSR finalized; enrollment closed
- WP1122 — undisclosed · Completed; Established RP2D
Biotech Distilled coverage (2)
- 2026-09-19 UPDATE: Moleculin Biotech (MBRX) - The Delisting Letter Arrives On Schedule 🔒 Paid
- 2026-08-26 Moleculin Biotech (MBRX) - Scientific Deep Dive for Annamycin and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.